泊洛沙姆188对镰状细胞病疼痛性血管闭塞发作的随机临床试验
这项3期随机双盲安慰剂对照国际试验纳入388例4至65岁镰状细胞病伴中重度疼痛性血管闭塞发作患者,比较泊洛沙姆188与安慰剂。结论不支持使用泊洛沙姆188治疗血管闭塞发作。
要点
- 泊洛沙姆188未显著缩短至末次肠外阿片类药物给药时间。
- 小于16岁亚组中泊洛沙姆188组时间更长(88.7 vs 71.9小时)。
核心结论
- 在镰状细胞病儿童和成人中,泊洛沙姆188未显著缩短血管闭塞发作期间至末次肠外阿片类药物给药的时间。
- 这些发现不支持使用泊洛沙姆188治疗血管闭塞发作。
研究设计与样本
- 3期随机双盲安慰剂对照多中心国际试验,2013年5月至2016年2月,覆盖12国60城66家医院。
- 纳入388例4至65岁镰状细胞病(血红蛋白SS、SC、S-β0或S-β+地中海贫血)伴急性中重度疼痛需住院的血管闭塞发作患者。
- 泊洛沙姆188组194例接受1小时100 mg/kg静脉负荷剂量后12至48小时30 mg/kg/h持续输注,安慰剂组194例。
主要发现
- 泊洛沙姆188组高胆红素血症更常见(12.7% vs 5.2%);安慰剂组低氧血症更常见(12.0% vs 5.3%)。
临床怎么用
- 现有证据不支持使用泊洛沙姆188治疗镰状细胞病血管闭塞发作。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although effective agents are available to prevent painful vaso-occlusive episodes of sickle cell disease (SCD), there are no disease-modifying therapies for ongoing painful vaso-occlusive episodes; treatment remains supportive. A previous phase 3 trial of poloxamer 188 reported shortened duration of painful vaso-occlusive episodes in SCD, particularly in children and participants treated with hydroxyurea. OBJECTIVE: To reassess the efficacy of poloxamer 188 for vaso-occlusive episodes. DESIGN, SETTING, AND PARTICIPANTS: Phase 3, randomized, double-blind, placebo-controlled, multicenter, international trial conducted from May 2013 to February 2016 that included 66 hospitals in 12 countries and 60 cities; 388 individuals with SCD (hemoglobin SS, SC, S-β0 thalassemia, or S-β+ thalassemia disease) aged 4 to 65 years with acute moderate to severe pain typical of painful vaso-occlusive episodes requiring hospitalization were included. INTERVENTIONS: A 1-hour 100-mg/kg loading dose of poloxamer 188 intravenously followed by a 12-hour to 48-hour 30-mg/kg/h continuous infusion (n = 194) or placebo (n = 194). MAIN OUTCOMES AND MEASURES: Time in hours from randomization to the last dose of parenteral opioids among all participants and among those younger than 16 years as a separate subgroup. RESULTS: Of 437 participants assessed for eligibility, 388 were randomized (mean age, 15.2 years; 176 [45.4%] female), the primary outcome was available for 384 (99.0%), 15-day follow-up contacts were available for 357 (92.0%), and 30-day follow-up contacts were available for 368 (94.8%). There was no significant difference between the groups for the mean time to last dose of parenteral opioids (81.8 h for the poloxamer 188 group vs 77.8 h for the placebo group; difference, 4.0 h [95% CI, -7.8 to 15.7]; geometric mean ratio, 1.2 [95% CI, 1.0-1.5]; P = .09). Based on a significant interaction of age and treatment (P = .01), there was a treatment difference in time from randomization to last administration of parenteral opioids for participants younger than 16 years (88.7 h in the poloxamer 188 group vs 71.9 h in the placebo group; difference, 16.8 h [95% CI, 1.7-32.0]; geometric mean ratio, 1.4 [95% CI, 1.1-1.8]; P = .008). Adverse events that were more common in the poloxamer 188 group than the placebo group included hyperbilirubinemia (12.7% vs 5.2%); those more common in the placebo group included hypoxia (12.0% vs 5.3%). CONCLUSIONS AND RELEVANCE: Among children and adults with SCD, poloxamer 188 did not significantly shorten time to last dose of parenteral opioids during vaso-occlusive episodes. These findings do not support the use of poloxamer 188 for vaso-occlusive episodes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01737814.
引用
- Casella JF, Barton BA, Kanter J, et al. Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial. JAMA. 2021. PMID: 33877274. doi:10.1001/jama.2021.3414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。